| . | . | . | . | Patterns of Relapse . | . | . | . |
|---|---|---|---|---|---|---|---|
| Study . | Treatment . | PFS (5 y) . | OS (5 y) . | Local . | Distant . | Combined . | Markers Alone . |
| ACNS0122 (N = 48) | Induction (6 cycles) Carboplatin/Etoposide alternating with ifosfamide/etoposide Followed by CSI (36Gy) plus tumor bed boost (54Gy) | 92% | 98% | 9 | 4 | 0 | 2 |
| SIOP’96(N = 116) | Induction (4 cycles) With cisplatin, etoposide, and ifosfamide Followed by IF-RT (54Gy) | 72% | 82% | 14 | 9 | 6 | 0 |
| ACNS1123 (N = 66 CR/PR) | Induction (6 cycles) Carboplatin/etoposide alternating with ifosfamide/etoposide Followed by WVI (30.6Gy) plus tumor bed boost (54Gy) | 88% (4 y) | 92% (4 y) | 0 | 7 | 1 | 0 |
| . | . | . | . | Patterns of Relapse . | . | . | . |
|---|---|---|---|---|---|---|---|
| Study . | Treatment . | PFS (5 y) . | OS (5 y) . | Local . | Distant . | Combined . | Markers Alone . |
| ACNS0122 (N = 48) | Induction (6 cycles) Carboplatin/Etoposide alternating with ifosfamide/etoposide Followed by CSI (36Gy) plus tumor bed boost (54Gy) | 92% | 98% | 9 | 4 | 0 | 2 |
| SIOP’96(N = 116) | Induction (4 cycles) With cisplatin, etoposide, and ifosfamide Followed by IF-RT (54Gy) | 72% | 82% | 14 | 9 | 6 | 0 |
| ACNS1123 (N = 66 CR/PR) | Induction (6 cycles) Carboplatin/etoposide alternating with ifosfamide/etoposide Followed by WVI (30.6Gy) plus tumor bed boost (54Gy) | 88% (4 y) | 92% (4 y) | 0 | 7 | 1 | 0 |
Abbreviations: CR, complete response; CSI, craniospinal irradiation; IF, involved field; M0, localized disease; OS, overall survival; PFS, progression-free survival; PR, partial response; WVI, whole ventricular irradiation.
| . | . | . | . | Patterns of Relapse . | . | . | . |
|---|---|---|---|---|---|---|---|
| Study . | Treatment . | PFS (5 y) . | OS (5 y) . | Local . | Distant . | Combined . | Markers Alone . |
| ACNS0122 (N = 48) | Induction (6 cycles) Carboplatin/Etoposide alternating with ifosfamide/etoposide Followed by CSI (36Gy) plus tumor bed boost (54Gy) | 92% | 98% | 9 | 4 | 0 | 2 |
| SIOP’96(N = 116) | Induction (4 cycles) With cisplatin, etoposide, and ifosfamide Followed by IF-RT (54Gy) | 72% | 82% | 14 | 9 | 6 | 0 |
| ACNS1123 (N = 66 CR/PR) | Induction (6 cycles) Carboplatin/etoposide alternating with ifosfamide/etoposide Followed by WVI (30.6Gy) plus tumor bed boost (54Gy) | 88% (4 y) | 92% (4 y) | 0 | 7 | 1 | 0 |
| . | . | . | . | Patterns of Relapse . | . | . | . |
|---|---|---|---|---|---|---|---|
| Study . | Treatment . | PFS (5 y) . | OS (5 y) . | Local . | Distant . | Combined . | Markers Alone . |
| ACNS0122 (N = 48) | Induction (6 cycles) Carboplatin/Etoposide alternating with ifosfamide/etoposide Followed by CSI (36Gy) plus tumor bed boost (54Gy) | 92% | 98% | 9 | 4 | 0 | 2 |
| SIOP’96(N = 116) | Induction (4 cycles) With cisplatin, etoposide, and ifosfamide Followed by IF-RT (54Gy) | 72% | 82% | 14 | 9 | 6 | 0 |
| ACNS1123 (N = 66 CR/PR) | Induction (6 cycles) Carboplatin/etoposide alternating with ifosfamide/etoposide Followed by WVI (30.6Gy) plus tumor bed boost (54Gy) | 88% (4 y) | 92% (4 y) | 0 | 7 | 1 | 0 |
Abbreviations: CR, complete response; CSI, craniospinal irradiation; IF, involved field; M0, localized disease; OS, overall survival; PFS, progression-free survival; PR, partial response; WVI, whole ventricular irradiation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
